Tvardi Therapeutics, Inc. (TVRD)

NASDAQ: TVRD · Real-Time Price · USD
5.16
-0.07 (-1.34%)
Oct 23, 2025, 3:43 PM EDT - Market open
-1.34%
Market Cap48.39M
Revenue (ttm)n/a
Net Income (ttm)-23.63M
Shares Out 9.38M
EPS (ttm)-3.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume450,017
Open5.25
Previous Close5.23
Day's Range4.91 - 5.35
52-Week Range4.91 - 43.65
Betan/a
AnalystsBuy
Price Target51.67 (+901.36%)
Earnings DateNov 21, 2025

About TVRD

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 12
Stock Exchange NASDAQ
Ticker Symbol TVRD
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for TVRD stock is "Buy." The 12-month stock price target is $51.67, which is an increase of 901.36% from the latest price.

Price Target
$51.67
(901.36% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered ...

8 days ago - PRNewsWire

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

NEW YORK--(BUSINESS WIRE)---- $TVRD #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (“Tvardi” or the “Co...

9 days ago - Business Wire

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

Tvardi Therapeutics Inc. (NASDAQ:TVRD) stock is falling on Monday with a session volume of 5.56 million versus the average volume of 42.08 thousand, as per data from Benzinga Pro.

10 days ago - Benzinga

Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 500 points on Monday.

Other symbols: AAAUDGPGLDGLDMIAUOUNZ
10 days ago - Benzinga

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

10 days ago - Business Wire

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

2 months ago - Business Wire

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

2 months ago - Business Wire

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

3 months ago - Business Wire

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Newly public Tvardi Therapeutics, Inc. TVRD is capturing investor attention following its recent reverse merger with Cara Therapeutics, Inc.

4 months ago - Benzinga

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

5 months ago - Business Wire

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

5 months ago - Business Wire

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, sma...

5 months ago - Business Wire

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

6 months ago - Business Wire

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.

Other symbols: CARA
6 months ago - GlobeNewsWire